IN2014DN01992A - - Google Patents
Info
- Publication number
- IN2014DN01992A IN2014DN01992A IN1992DEN2014A IN2014DN01992A IN 2014DN01992 A IN2014DN01992 A IN 2014DN01992A IN 1992DEN2014 A IN1992DEN2014 A IN 1992DEN2014A IN 2014DN01992 A IN2014DN01992 A IN 2014DN01992A
- Authority
- IN
- India
- Prior art keywords
- methyl
- aminosulfonyl
- thiazol
- pyridinyl
- phenyl
- Prior art date
Links
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 abstract 2
- BOMPQMCBXWOXAZ-UHFFFAOYSA-N O.CS(O)(=O)=O.CNC(=O)Cc1ccc(cc1)-c1ccccn1 Chemical compound O.CS(O)(=O)=O.CNC(=O)Cc1ccc(cc1)-c1ccccn1 BOMPQMCBXWOXAZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- OIXMUQLVDNPHNS-UHFFFAOYSA-N methanesulfonic acid;hydrate Chemical compound O.CS(O)(=O)=O OIXMUQLVDNPHNS-UHFFFAOYSA-N 0.000 abstract 1
- FCVMHSMWASHTGN-UHFFFAOYSA-N n-methyl-2-(4-pyridin-2-ylphenyl)acetamide Chemical compound C1=CC(CC(=O)NC)=CC=C1C1=CC=CC=N1 FCVMHSMWASHTGN-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11007803A EP2573085A1 (en) | 2011-09-26 | 2011-09-26 | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| PCT/EP2012/068958 WO2013045491A1 (en) | 2011-09-26 | 2012-09-26 | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN01992A true IN2014DN01992A (cs) | 2015-05-15 |
Family
ID=46889071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1992DEN2014 IN2014DN01992A (cs) | 2011-09-26 | 2012-09-26 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9119786B2 (cs) |
| EP (1) | EP2573085A1 (cs) |
| JP (1) | JP6043356B2 (cs) |
| KR (1) | KR20140066705A (cs) |
| CN (1) | CN103842360B (cs) |
| AU (1) | AU2012314473B2 (cs) |
| IN (1) | IN2014DN01992A (cs) |
| MX (1) | MX364094B (cs) |
| RU (1) | RU2606628C2 (cs) |
| WO (1) | WO2013045491A1 (cs) |
| ZA (1) | ZA201401774B (cs) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| AU2014217962A1 (en) * | 2013-02-12 | 2015-09-17 | Aicuris Gmbh & Co. Kg | Helicase-primase inhibitors for use in a method of treating Alzheimer's Disease |
| MX2017003916A (es) * | 2014-09-26 | 2017-06-30 | Millendo Therapeutics Inc | Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n'-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma. |
| SI3135275T1 (sl) * | 2015-08-27 | 2020-09-30 | Grindeks, A Joint Stock Company | Farmacevtski pripravek, ki je sposoben vključitve lenalidomida v različnih kristaliničnih modifikacijah |
| PT3544976T (pt) | 2016-11-28 | 2021-05-18 | Aicuris Anti Infective Cures Gmbh | Hemi-hidrato da base livre de n-[5-(aminossulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricação e suas utilizações |
| CA3253408A1 (en) | 2016-11-28 | 2025-06-16 | Aic316 Gmbh | A maleate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide |
| AR110250A1 (es) | 2016-11-28 | 2019-03-13 | Aicuris Anti Infective Cures Gmbh | Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida |
| CN110831577B (zh) | 2017-06-28 | 2023-11-28 | 艾库里斯有限及两合公司 | 包含抗病毒化合物的阴道内施用型装置 |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| JP2025527943A (ja) | 2022-08-29 | 2025-08-25 | アセンブリー・バイオサイエンシーズ・インコーポレイテッド | 新規な結晶形態 |
| JP2025527942A (ja) | 2022-08-29 | 2025-08-25 | アセンブリー・バイオサイエンシーズ・インコーポレイテッド | 新規な結晶形態 |
| CN119816296A (zh) | 2022-08-29 | 2025-04-11 | 组装生物科学股份有限公司 | 用于疱疹病毒的药物组合物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3720757A1 (de) * | 1987-06-24 | 1989-01-05 | Bayer Ag | Dhp-manteltablette |
| US6348503B1 (en) | 1996-02-12 | 2002-02-19 | Meryl J. Squires | Method and topical treatment composition for herpesvirus hominis |
| US6355684B1 (en) * | 1990-10-11 | 2002-03-12 | Meryl J. Squires | Antimicrobial treatment for herpes simplex virus and other infectious diseases |
| US9662360B2 (en) | 2008-10-09 | 2017-05-30 | Meritus Corporation | Treatment of herpes, pseudomonas, staph, and hepatitis |
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| EP1319185A1 (en) * | 2000-06-15 | 2003-06-18 | Bayer Aktiengesellschaft | Method for identifying compounds with anti-herpes activity |
| DE10129717A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10129716A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10129714A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
| DE10131128A1 (de) * | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| DE102005014248A1 (de) | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| JP2007314516A (ja) | 2006-04-25 | 2007-12-06 | Daiichi Sankyo Co Ltd | ２以上の置換基を有するベンゼン化合物を含有する医薬 |
| CN101490001A (zh) | 2006-06-09 | 2009-07-22 | Icos股份有限公司 | 用作dp-2拮抗剂的取代的苯乙酸 |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| AU2014217962A1 (en) * | 2013-02-12 | 2015-09-17 | Aicuris Gmbh & Co. Kg | Helicase-primase inhibitors for use in a method of treating Alzheimer's Disease |
| MX2017003916A (es) | 2014-09-26 | 2017-06-30 | Millendo Therapeutics Inc | Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n'-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma. |
| CA3253408A1 (en) | 2016-11-28 | 2025-06-16 | Aic316 Gmbh | A maleate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide |
| PT3544976T (pt) | 2016-11-28 | 2021-05-18 | Aicuris Anti Infective Cures Gmbh | Hemi-hidrato da base livre de n-[5-(aminossulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricação e suas utilizações |
| KR102335327B1 (ko) | 2017-04-28 | 2021-12-03 | 현대자동차 주식회사 | 수냉식 이지알 쿨러 |
| CN110831577B (zh) | 2017-06-28 | 2023-11-28 | 艾库里斯有限及两合公司 | 包含抗病毒化合物的阴道内施用型装置 |
-
2011
- 2011-09-26 EP EP11007803A patent/EP2573085A1/en not_active Withdrawn
-
2012
- 2012-09-26 JP JP2014532367A patent/JP6043356B2/ja active Active
- 2012-09-26 RU RU2014116621A patent/RU2606628C2/ru active
- 2012-09-26 IN IN1992DEN2014 patent/IN2014DN01992A/en unknown
- 2012-09-26 MX MX2014003623A patent/MX364094B/es active IP Right Grant
- 2012-09-26 KR KR1020147004027A patent/KR20140066705A/ko not_active Ceased
- 2012-09-26 CN CN201280046748.4A patent/CN103842360B/zh active Active
- 2012-09-26 WO PCT/EP2012/068958 patent/WO2013045491A1/en not_active Ceased
- 2012-09-26 AU AU2012314473A patent/AU2012314473B2/en active Active
-
2013
- 2013-11-01 US US14/069,850 patent/US9119786B2/en active Active
-
2014
- 2014-03-11 ZA ZA2014/01774A patent/ZA201401774B/en unknown
-
2015
- 2015-08-31 US US14/840,690 patent/US9889124B2/en active Active
- 2015-08-31 US US14/840,763 patent/US9592225B2/en active Active
-
2017
- 2017-08-22 US US15/683,127 patent/US10137117B2/en not_active Ceased
-
2020
- 2020-11-25 US US17/104,028 patent/USRE49697E1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014003623A (es) | 2014-05-30 |
| US9889124B2 (en) | 2018-02-13 |
| US9592225B2 (en) | 2017-03-14 |
| ZA201401774B (en) | 2015-12-23 |
| CN103842360B (zh) | 2016-06-22 |
| RU2606628C2 (ru) | 2017-01-10 |
| JP6043356B2 (ja) | 2016-12-14 |
| USRE49697E1 (en) | 2023-10-17 |
| US20170348297A1 (en) | 2017-12-07 |
| WO2013045491A1 (en) | 2013-04-04 |
| AU2012314473A1 (en) | 2014-02-06 |
| US10137117B2 (en) | 2018-11-27 |
| KR20140066705A (ko) | 2014-06-02 |
| MX364094B (es) | 2019-04-12 |
| US20150366849A1 (en) | 2015-12-24 |
| CN103842360A (zh) | 2014-06-04 |
| US20140065224A1 (en) | 2014-03-06 |
| US9119786B2 (en) | 2015-09-01 |
| US20160008341A1 (en) | 2016-01-14 |
| AU2012314473B2 (en) | 2015-09-17 |
| RU2014116621A (ru) | 2015-11-10 |
| JP2014527995A (ja) | 2014-10-23 |
| EP2573085A1 (en) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN01992A (cs) | ||
| IN2014DN01993A (cs) | ||
| MX2014005635A (es) | Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida. | |
| MY172924A (en) | Neprilysin inhibitors | |
| IN2014CN04530A (cs) | ||
| SI2318004T1 (sl) | Farmacevtski sestavki, ki vsebujejo kristalinično obliko Y posakonazola | |
| PL2785711T3 (pl) | Pochodne 2-(fenylo lub piryd-3-ylo)aminopirymidyny jako modulatory kinazy lrrk2 do leczenia choroby parkinsona | |
| MY163394A (en) | Substituted aminobutyric derivates as neprilysin inhibitors | |
| SG195106A1 (en) | Trpv4 antagonists | |
| ZA201206254B (en) | Novel salts for the manufacture of pharmaceutical compositions | |
| IL220707A (en) | Annotations 2– (phenyl / heteroaryl) - [3,1] oxazolo [4,5– d] pyrimidine, process for preparation and pharmaceutical preparations containing them | |
| MY176244A (en) | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist | |
| PH12016500322A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
| PL2770844T3 (pl) | Pochodząca z pomidorów kompozycja zawierająca zwiększone poziomy 5’-monofosforanu inozyny | |
| EP2514720A4 (en) | PREPARATION FOR HIGH DENSITY ZNO NANOPOUNTS | |
| ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
| MX364104B (es) | Moduladores del receptor cxcr7. | |
| IN2014DN06122A (cs) | ||
| MA33883B1 (fr) | Procédé de synthèse et forme cristalline du chlorhydrate de 4-{3-[cishexanhydrocyclopenta[c] pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent | |
| PL2612850T3 (pl) | Postać krystaliczna delta soli argininy peryndoprylu, sposób jej wytwarzania oraz kompozycje farmaceutyczne, które ją zawierają | |
| MX2013012773A (es) | Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. | |
| IL228462B (en) | The film-forming composition for sustained release depends on the ph of an active ingredient | |
| IN2015DN03869A (cs) | ||
| MX346497B (es) | Compuestos para la diferenciacion de celulas madre mejorada en hepatocitos. | |
| MX351994B (es) | Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico. |